FDA approves painkiller said to thwart addiction
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years


What happened
The Food and Drug Administration Thursday approved a new class of pain pill that is not addictive like opioids. Suzetrigine, being sold as Journavx by Vertex Pharmaceuticals, is the first new pharmaceutical treatment for pain to win FDA approval in more than 20 years.
Who said what
Opioids work by binding to receptors in the brain that receive pain signals from nerves around the body, but "those chemical interactions also give rise to opioids' addictive effects," The Associated Press said. But while prescription opioids have helped fuel an epidemic of addiction and overdoses, suzetrigine "works differently," intercepting pain signals before they reach the brain.
In two clinical trials submitted by Vertex, suzetrigine was more effective than a placebo at treating short-term pain in people recovering from stomach and foot surgery, and on par with a combined acetaminophen-hydrocodone pill, like Vicodin.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What next?
Journavx was approved to treat acute pain in adults. But at a list price of $15.50 a pill, it "faces some hurdles in winning over physicians, hospitals and insurance companies," The Washington Post said. The new painkiller is promising because "there are a number of people who, once they have an opioid, want an opioid constantly," University of Washington pain expert Dr. John Loeser said to The New York Times. But acetaminophen-opioid pills are "dirt cheap."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Rafi Schwartz has worked as a politics writer at The Week since 2022, where he covers elections, Congress and the White House. He was previously a contributing writer with Mic focusing largely on politics, a senior writer with Splinter News, a staff writer for Fusion's news lab, and the managing editor of Heeb Magazine, a Jewish life and culture publication. Rafi's work has appeared in Rolling Stone, GOOD and The Forward, among others.
-
Air strikes in the Caribbean: Trump’s murky narco-war
Talking Point Drug cartels ‘don’t follow Marquess of Queensberry Rules’, but US military air strikes on speedboats rely on strained interpretation of ‘invasion’
-
A tour of Sri Lanka’s beautiful north
The Week Recommends ‘Less frenetic’ than the south, this region is full of beautiful wildlife, historical sites and resorts
-
Crossword: September 14, 2025
The Week's daily crossword puzzle
-
Quit-smoking ads are being put out
Under the radar The dissolution of a government-funded campaign could lead to more smokers in the future
-
Sloth fever shows no signs of slowing down
The explainer The vector-borne illness is expanding its range
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Forever chemicals were found in reusable menstrual products. That is nothing new for women.
Under the Radar Toxic chemicals are all too common in such products
-
Why the FDA wants to restrict kratom-related products
In the Spotlight The compound is currently sold across the United States
-
Not just a number: how aging rates vary by country
The explainer Inequality is a key factor
-
Children's health has declined in the US
The Explainer It's likely a sign of larger systemic issues